Corium, LLC operates as a biopharmaceutical company focused on the development, manufacturing, and commercialization of specialty transdermal and neuroscience therapies. The company develops and manufactures transdermal products and therapies for neuroscience disorders, including the donepezil transdermal system, and offers therapies for conditions such as attention-deficit/hyperactivity disorder and Alzheimer's disease. Corium supports scientific advancement by providing study drugs, research funding, and medical educational grants for healthcare providers, patients, and caregivers. The company offers copay assistance, access support, educational resources, and medical information services, including adverse event and product quality complaint reporting. Corium serves health care organizations, associations, medical specialty societies, academic institutions, private and governmental institutions, and clinicians. The company was founded in 2002 and is based in Cambridge, Massachusetts.